Pesquisando por: "Blood samples in a lab" - Fotoarena - Agência de fotojornalismo

RC2CPP950QY2 Field lab assistants collect a blood sample from a bat at a field laboratory as they research the Nipah virus in the Shuvarampur area of Faridpur, Bangladesh, September 14, 2021. To match Special Report GLOBAL-PANDEMICS/BATS-SPILLOVER REUTERS/Mohammad Ponir Hossain

RC2IQX9L8CZ3 FILE PHOTO: A nurse draws a blood sample for an HIV test at the lab of the NGO "Accion Solidaria" (Solidarity Action) in Caracas, Venezuela, November 28, 2018. Picture taken November 28, 2018. REUTERS/Marco Bello/File Photo

RC2ZWJ9NQCMF Aisha Abdi Mohamed, a laboratory technician, holds a blood sample inside the Medipark Diagnostics lab that runs tests for the coronavirus disease (COVID-19), in Mogadishu, Somalia October 14, 2020. Picture taken October 14, 2020. REUTERS/Feisal Omar

RC2ZWJ94POBD Aisha Abdi Mohamed, a laboratory technician, takes a blood sample from a man inside the Medipark Diagnostics Lab that runs tests for the coronavirus disease (COVID-19), in Mogadishu, Somalia October 14, 2020. Picture taken October 14, 2020. REUTERS/Feisal Omar

RC2ZWJ9A188T Aisha Abdi Mohamed, a laboratory technician, takes a blood sample from a man inside the Medipark Diagnostics Lab that runs tests for the coronavirus disease (COVID-19), in Mogadishu, Somalia October 14, 2020. Picture taken October 14, 2020. REUTERS/Feisal Omar

RC2NVH9G95JL FILE PHOTO: Blood samples from patients infected with the coronavirus disease (COVID-19) are prepared for analysis in the Blood Processing Lab in the Cambridge Institute of Therapeutic Immunology and Infectious Disease, in Cambridge, Britain May 21, 2020. Kirsty Wigglesworth/Pool via REUTERS/File Photo

RC2C8H9JDHEG Researchers collect blood samples from a horseshoe bat for coronavirus disease (COVID-19) test at a lab, amid concerns that the bats may pose a threat to local residents, in Chonburi province, Thailand, June 12, 2020. Picture taken June 12, 2020. Department of National Parks, Wildlife and Plant Conservation (DNP)/Handout via REUTERS ATTENTION EDITORS - THIS IMAGE WAS PROVIDED BY A THIRD PARTY. NO RESALES. NO ARCHIVES.

RC2C8H9G7SC8 A blood sample from a horseshoe bat for coronavirus disease (COVID-19) test is pictured at a lab, amid concerns that the bats may pose a threat to local residents, in Chonburi province, Thailand, June 12, 2020. Picture taken June 12, 2020. Department of National Parks, Wildlife and Plant Conservation (DNP)/Handout via REUTERS ATTENTION EDITORS - THIS IMAGE WAS PROVIDED BY A THIRD PARTY. NO RESALES. NO ARCHIVES.

RC2C8H95F3T5 Researchers collect blood samples from a horseshoe bat for coronavirus disease (COVID-19) test at a lab, amid concerns that the bats may pose a threat to local residents, in Chonburi province, Thailand, June 12, 2020. Picture taken June 12, 2020. Department of National Parks, Wildlife and Plant Conservation (DNP)/Handout via REUTERS ATTENTION EDITORS - THIS IMAGE WAS PROVIDED BY A THIRD PARTY. NO RESALES. NO ARCHIVES.

RC2C8H91RTHX Researchers collect blood samples from a horseshoe bat for coronavirus disease (COVID-19) test at a lab, amid concerns that the bats may pose a threat to local residents, in Chonburi province, Thailand, June 11, 2020. Picture taken June 11, 2020. Department of National Parks, Wildlife and Plant Conservation (DNP)/Handout via REUTERS ATTENTION EDITORS - THIS IMAGE WAS PROVIDED BY A THIRD PARTY. NO RESALES. NO ARCHIVES. TPX IMAGES OF THE DAY

RC2MTG9Q427B Francesca Nice, PHD Research Associate prepares blood samples from patients infected with the coronavirus disease (COVID-19) for analysis as part of the TACTIC-R trial, in the Blood Processing Lab in the Cambridge Institute of Therapeutic Immunology and Infectious Disease, in Cambridge, Britain May 21, 2020. Picture taken May 21, 2020. The new trial known as TACTIC-R is testing whether existing drugs will help prevent the body's immune system from overreacting, which scientists hope could prevent organ failure and death in COVID-19 patients. Kirsty Wigglesworth/Pool via REUTERS

RC2MTG9KLMJ7 Blood samples from patients infected with the coronavirus disease (COVID-19) are prepared for analysis as part of the TACTIC-R trial, in the Blood Processing Lab in the Cambridge Institute of Therapeutic Immunology and Infectious Disease, in Cambridge, Britain May 21, 2020. Picture taken May 21, 2020. The new trial known as TACTIC-R is testing whether existing drugs will help prevent the body's immune system from overreacting, which scientists hope could prevent organ failure and death in COVID-19 patients. Kirsty Wigglesworth/Pool via REUTERS

RC2MTG9KIT7L Francesca Nice, PHD Research Associate prepares blood samples from patients infected with the coronavirus disease (COVID-19) for analysis as part of the TACTIC-R trial, in the Blood Processing Lab in the Cambridge Institute of Therapeutic Immunology and Infectious Disease, in Cambridge, Britain May 21, 2020. Picture taken May 21, 2020. The new trial known as TACTIC-R is testing whether existing drugs will help prevent the body's immune system from overreacting, which scientists hope could prevent organ failure and death in COVID-19 patients. Kirsty Wigglesworth/Pool via REUTERS

RC2MTG9K0B6I Blood samples from patients infected with the coronavirus disease (COVID-19) are prepared for analysis as part of the TACTIC-R trial, in the Blood Processing Lab in the Cambridge Institute of Therapeutic Immunology and Infectious Disease, in Cambridge, Britain May 21, 2020. Picture taken May 21, 2020. The new trial known as TACTIC-R is testing whether existing drugs will help prevent the body's immune system from overreacting, which scientists hope could prevent organ failure and death in COVID-19 patients. Kirsty Wigglesworth/Pool via REUTERS

RC2MTG9HJ5Z9 Francesca Nice, PHD Research Associate prepares blood samples from patients infected with the coronavirus disease (COVID-19) for analysis as part of the TACTIC-R trial, in the Blood Processing Lab in the Cambridge Institute of Therapeutic Immunology and Infectious Disease, in Cambridge, Britain May 21, 2020. Picture taken May 21, 2020. The new trial known as TACTIC-R is testing whether existing drugs will help prevent the body's immune system from overreacting, which scientists hope could prevent organ failure and death in COVID-19 patients. Kirsty Wigglesworth/Pool via REUTERS

RC2MTG99MUDF Blood samples from patients infected with the coronavirus disease (COVID-19) are prepared for analysis as part of the TACTIC-R trial, in the Blood Processing Lab in the Cambridge Institute of Therapeutic Immunology and Infectious Disease, in Cambridge, Britain May 21, 2020. Picture taken May 21, 2020. The new trial known as TACTIC-R is testing whether existing drugs will help prevent the body's immune system from overreacting, which scientists hope could prevent organ failure and death in COVID-19 patients. Kirsty Wigglesworth/Pool via REUTERS

RC2MTG97N0RM Blood samples from patients infected with the coronavirus disease (COVID-19) are prepared for analysis as part of the TACTIC-R trial, in the Blood Processing Lab in the Cambridge Institute of Therapeutic Immunology and Infectious Disease, in Cambridge, Britain May 21, 2020. Picture taken May 21, 2020. The new trial known as TACTIC-R is testing whether existing drugs will help prevent the body's immune system from overreacting, which scientists hope could prevent organ failure and death in COVID-19 patients. Kirsty Wigglesworth/Pool via REUTERS

RC2F5G9MU7KN Andrew Lee, supervisor in the blood draw lab that receives COVID-19 samples, poses for a portrait at the University of Washington Medical Center - Montlake during the coronavirus disease (COVID-19) outbreak, in Seattle, Washington, U.S. April 15, 2020. REUTERS/David Ryder

RC2PYD9BOUXL University of Colorado Researcher Julia Squeri stores blood samples in a mobile lab during a study on the effects of cannabis in Longmont, Colorado, U.S., December 19, 2019. RREUTERS/Kevin Mohatt

RC2PYD998VHB University of Colorado Researcher Julia Squeri works in a mobile lab to gather blood samples from a study participant during a study on the effects of cannabis, in Longmont, Colorado, U.S., December 19, 2019. REUTERS/Kevin Mohatt

RC129F537A50 A nurse draws a blood sample for an HIV test at the lab of the NGO "Accion Solidaria" (Solidarity Action) in Caracas, Venezuela, November 28, 2018. Picture taken November 28, 2018. REUTERS/Marco Bello

RC1E1647EC70 FILE PHOTO: A health technician analyses blood samples for tuberculosis testing in a high-tech tuberculosis lab in Carabayllo in Lima, Peru May 19, 2016. REUTERS/Mariana Bazo/File Photo

RC17D8F07AF0 FILE PHOTO: A health technician analyses blood samples for tuberculosis testing in a high-tech tuberculosis lab in Carabayllo in Lima, Peru May 19, 2016. REUTERS/Mariana Bazo/File Photo

S1AEUOHDMWAA A health technician analyses blood samples for tuberculosis testing in a high-tech tuberculosis lab in Carabayllo in Lima, Peru May 19, 2016. REUTERS/Mariana Bazo SEARCH "TB HOPE" FOR THIS STORY. SEARCH "THE WIDER IMAGE" FOR ALL STORIES.

S1AEUOHDOHAA A health technician analyses blood samples for tuberculosis testing in a high-tech tuberculosis lab in Carabayllo in Lima, Peru May 19, 2016. REUTERS/Mariana Bazo SEARCH "TB HOPE" FOR THIS STORY. SEARCH "THE WIDER IMAGE" FOR ALL STORIES. TPX IMAGES OF THE DAY

D1AESYOJZLAB A lab technician arranges test tubes with blood samples from patients who were tested for Zika, at the maternity ward of the Hospital Escuela in Tegucigalpa Honduras, April 15, 2016. REUTERS/Jorge Cabrera

GF10000295165 Test tubes with blood samples from patients who could possibly be infected with Zika are seen in a lab desk in Caracas, February 3, 2016. REUTERS/Marco Bello

GF10000295164 Test tubes with blood samples from patients who could possibly be infected with Zika are seen in a lab desk in Caracas, February 3, 2016. REUTERS/Marco Bello

GM1EAAS07UB01 Veterinarians clean the teeth of Tango, an eleven-year-old male jaguar, as it undergoes a full medical examination at the Buenos Aires Zoo October 27, 2014. Argentina's rare jaguar was added to Buenos Aires Zoo's DNA bank on Monday as conservationists step up efforts to save the big cat species that is on the brink of extinction. The 11-year-old jaguar called Tango could be the key to preserving the species for future generations. At the zoo's Biotechnology Reproduction Lab, vets took blood, hair and semen samples from Tango to be stored. REUTERS/Enrique Marcarian (ARGENTINA - Tags: ANIMALS SOCIETY TPX IMAGES OF THE DAY)

GM1EAAS071901 Adrian Sestelo, lab director at the Biotechnology Reproduction Lab, extracts semen samples from Tango, an eleven-year-old male jaguar, as it undergoes a full medical examination at the Buenos Aires Zoo October 27, 2014. Argentina's rare jaguar was added to Buenos Aires Zoo's DNA bank on Monday as conservationists step up efforts to save the big cat species that is on the brink of extinction. The 11-year-old jaguar called Tango could be the key to preserving the species for future generations. At the zoo's Biotechnology Reproduction Lab, vets took blood, hair and semen samples from Tango to be stored. REUTERS/Enrique Marcarian (ARGENTINA - Tags: ANIMALS SOCIETY)

GM1EAAS06Y901 A veterinarian cuts the claws of Tango, an eleven-year-old male jaguar, as it undergoes a full medical examination at the Buenos Aires Zoo October 27, 2014. Argentina's rare jaguar was added to Buenos Aires Zoo's DNA bank on Monday as conservationists step up efforts to save the big cat species that is on the brink of extinction. The 11-year-old jaguar called Tango could be the key to preserving the species for future generations. At the zoo's Biotechnology Reproduction Lab, vets took blood, hair and semen samples from Tango to be stored. REUTERS/Enrique Marcarian (ARGENTINA - Tags: ANIMALS SOCIETY)

GM1EAAS06W801 Veterinarians prepare Tango, an eleven-year-old male jaguar, for a full medical examination at the Buenos Aires Zoo October 27, 2014. Argentina's rare jaguar was added to Buenos Aires Zoo's DNA bank on Monday as conservationists step up efforts to save the big cat species that is on the brink of extinction. The 11-year-old jaguar called Tango could be the key to preserving the species for future generations. At the zoo's Biotechnology Reproduction Lab, vets took blood, hair and semen samples from Tango to be stored. REUTERS/Enrique Marcarian (ARGENTINA - Tags: ANIMALS SOCIETY)

GM1EAAS06QG01 Veterinarians insert a tube inside the mouth of Tango, an eleven-year-old male jaguar, during a full medical examination at the Buenos Aires Zoo October 27, 2014. Argentina's rare jaguar was added to Buenos Aires Zoo's DNA bank on Monday as conservationists step up efforts to save the big cat species that is on the brink of extinction. The 11-year-old jaguar called Tango could be the key to preserving the species for future generations. At the zoo's Biotechnology Reproduction Lab, vets took blood, hair and semen samples from Tango to be stored. REUTERS/Enrique Marcarian (ARGENTINA - Tags: ANIMALS SOCIETY)

GM1EAAS062A01 Veterinarians prepare Tango, an eleven-year-old male jaguar, for a full medical examination at the Buenos Aires Zoo October 27, 2014. Argentina's rare jaguar was added to Buenos Aires Zoo's DNA bank on Monday as conservationists step up efforts to save the big cat species that is on the brink of extinction. The 11-year-old jaguar called Tango could be the key to preserving the species for future generations. At the zoo's Biotechnology Reproduction Lab, vets took blood, hair and semen samples from Tango to be stored. REUTERS/Enrique Marcarian (ARGENTINA - Tags: ANIMALS HEALTH SOCIETY)

GM1EAAS05O301 A veterinarian takes a picture inside the mouth of Tango, an eleven-year-old male jaguar, as it undergoes a full medical examination at the Buenos Aires Zoo October 27, 2014. Argentina's rare jaguar was added to Buenos Aires Zoo's DNA bank on Monday as conservationists step up efforts to save the big cat species that is on the brink of extinction. The 11-year-old jaguar called Tango could be the key to preserving the species for future generations. At the zoo's Biotechnology Reproduction Lab, vets took blood, hair and semen samples from Tango to be stored. REUTERS/Enrique Marcarian (ARGENTINA - Tags: ANIMALS HEALTH SOCIETY)

GM1E63U0LW601 A lab assistant holds a frozen urine sample before storing it at Biobank, the world's largest blood and urine sample freezer near Manchester, northern England, in this March 18, 2010 file picture. Francis Collins, who helped map the human genome, did not get around to having his own genes analyzed until last summer. And he was surprised by what he learned. Collins has a predisposition for type-2 diabetes, something he had never suspected. The lanky, former director of the National Human Genome Research Institute (NHGRI) discovered this through tests offered by Navigenics, 23andMe and DecodeMe -- companies that charge customers a few hundred dollars for a peek at their genetic makeup. Picture taken March 18, 2010. To match Special Report SCIENCE/GENOME REUTERS/Phil Noble (BRITAIN - Tags: HEALTH SCI TECH)

GM1E63U0LMT01 A lab assistant holds a frozen urine sample before storing it at Biobank, the world's largest blood and urine sample freezer near Manchester, northern England, in this March 18, 2010 file picture. Francis Collins, who helped map the human genome, did not get around to having his own genes analyzed until last summer. And he was surprised by what he learned. Collins has a predisposition for type-2 diabetes, something he had never suspected. The lanky, former director of the National Human Genome Research Institute (NHGRI) discovered this through tests offered by Navigenics, 23andMe and DecodeMe -- companies that charge customers a few hundred dollars for a peek at their genetic makeup. Picture taken March 18, 2010. To match Special Report SCIENCE/GENOME REUTERS/Phil Noble (BRITAIN - Tags: HEALTH SCI TECH)

GM1E5AM0IQH01 A research technician looks at a test sample in the new anti-doping lab set up for the 2010 Olympic Winter Games in Richmond, British Columbia October 21, 2009. The lab is one of world's most state-of-the-art anti-doping labs and will be used to process over 2,000 urine and blood samples during the 2010 Olympic Winter Games. REUTERS/Andy Clark (CANADA SPORT OLYMPICS HEALTH SCI TECH)

GM1E5AM0IQC01 Research technician Gerard Dussault works on test samples following the opening of the anti-doping lab for the upcoming 2010 Olympic Winter Games in Richmond, British Columbia October 21, 2009. The lab is one of world's most state-of-the-art anti-doping labs and will be used to process over 2,000 urine and blood samples during the 2010 Olympic Winter Games. REUTERS/Andy Clark (CANADA SPORT OLYMPICS HEALTH SCI TECH)

GM1E5AM0IQ401 Dr. Christiane Ayotte talks about areas in the brand new anti-doping lab set up at the Olympic Oval in Richmond, British Columbia October 21, 2009. The lab is one of world's most state-of-the-art anti-doping labs and will be used to process over 2,000 urine and blood samples during the 2010 Olympic Winter Games. REUTERS/Andy Clark (CANADA SPORT OLYMPICS HEALTH SCI TECH)

GM1E5AM0IC101 Dr. Christiane Ayotte talks about areas of the brand new anti-doping lab set up at the Olympic Oval in Richmond, British Columbia October 21, 2009. The lab is one of world's most state-of-the-art anti-doping labs and will be used to process over 2,000 urine and blood samples during the 2010 Olympic Winter Games. REUTERS/Andy Clark (CANADA SPORT OLYMPICS HEALTH IMAGES OF THE DAY)

GM1E5AM0I0S01 Research Technician Anahid Fakirian looks at a test sample in the new anti-doping lab set up for the 2010 Olympic Winter Games in Richmond, British Columbia, October 21, 2009. The lab is one of world's most state-of-the-art anti-doping labs and will be used to process over 2,000 urine and blood samples during the 2010 Olympic Winter Games. REUTERS/Andy Clark (CANADA SPORT OLYMPICS HEALTH)

GM1E5AM0HON01 Dr. Christiane Ayotte points out areas of the brand new anti-doping lab set up at the Olympic Oval in Richmond, British Columbia October 21, 2009. The lab is one of world's most state-of-the-art anti-doping labs and will be used to process over 2,000 urine and blood samples during the 2010 Olympic Winter Games. REUTERS/Andy Clark (CANADA SPORT OLYMPICS HEALTH)

PM1E5411DP601 French researchers of the Etablissement Francais du Sang (French Blood Institution) Doctors Sylvie Chapel (L) and Pascal Bailly (R) pose in their laboratory in Marseille, April 1, 2009. Dr Claude Bagnis (not seen), head of the molecular haematology lab at EFS, and his team have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411BHX01 Dr Claude Bagnis, head of the molecular haematology lab at the Etablissement Francais du Sang (French Blood Institution) examines cells by fluorescence with an electron microscope in his laboratory in Marseille, April 1, 2009. Dr Bagnis and his team of researchers at EFS have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411BFF01 Dr Claude Bagnis, head of the molecular haematology lab at the Etablissement Francais du Sang (French Blood Institution) holds a tube as he collects gene transfer vectors in his laboratory in Marseille, April 1, 2009. Dr Bagnis and his team of researchers at EFS have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411BF401 Dr Claude Bagnis, head of the molecular haematology lab at the Etablissement Francais du Sang (French Blood Institution) collects gene transfer vectors in his laboratory in Marseille, April 1, 2009. Dr Bagnis and his team of researchers at EFS have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411BDZ01 Dr Claude Bagnis, head of the molecular haematology lab at the Etablissement Francais du Sang (French Blood Institution) displays a tube as he collects gene transfer vectors in his laboratory in Marseille, April 1, 2009. Dr Bagnis and his team of researchers at EFS have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411BDB01 Dr Claude Bagnis, head of the molecular haematology lab at the Etablissement Francais du Sang (French Blood Institution) displays a tube as he collects gene transfer vectors in his laboratory in Marseille, April 1, 2009. Dr Bagnis and his team of researchers at EFS have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411BCQ01 Dr Claude Bagnis, head of the molecular haematology lab at the Etablissement Francais du Sang (French Blood Institution) examines cells by fluorescence with an electron microscope in his laboratory in Marseille, April 1, 2009. Dr Bagnis and his team of researchers at EFS have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411AL001 French researchers of the Etablissement Francais du Sang (French Blood Institution), Doctors Claude Bagnis (R), Sylvie Chapel (C) and Pascal Bailly (L) pose in their laboratory in Marseille, April 1, 2009. Dr Bagnis, head of the molecular haematology lab at EFS, and his team have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411AHX01 Dr Claude Bagnis, head of the molecular haematology lab at the Etablissement Francais du Sang (French Blood Institution) examines cells by fluorescence with an electron microscope in his laboratory in Marseille, April 1, 2009. Dr Bagnis and his team of researchers at EFS have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411ADM01 Dr Claude Bagnis, head of the molecular haematology lab at the Etablissement Francais du Sang (French Blood Institution) collects gene transfer vectors in his laboratory in Marseille, April 1, 2009. Dr Bagnis and his team of researchers at EFS have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411A2V01 French researchers of the Etablissement Francais du Sang (French Blood Institution), Doctors Claude Bagnis (R), Pascal Bailly (C) and Sylvie Chapel (L) pose in their laboratory in Marseille, April 1, 2009. Dr Bagnis, head of the molecular haematology lab at EFS, and his team have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411A2501 French researchers of the Etablissement Francais du Sang (French Blood Institution), Doctors Claude Bagnis (R), Sylvie Chapel (C) and Pascal Bailly (L) pose in their laboratory in Marseille, April 1, 2009. Dr Bagnis, head of the molecular haematology lab at EFS, and his team have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

PM1E5411A1901 French researchers of the Etablissement Francais du Sang (French Blood Institution), Doctors Claude Bagnis (R), Sylvie Chapel (C) and Pascal Bailly (L) pose in their laboratory in Marseille, April 1, 2009. Dr Bagnis, head of the molecular haematology lab at EFS, and his team have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

GM1E542011B01 Claude Bagnis, head of the molecular haematology lab at the Etablissement Francais du Sang (French Blood Institution) examines cells by fluorescence with an electron microscope in his laboratory in Marseille April 1, 2009. Bagnis and his team of researchers at EFS have successfully genetically modified human red blood cells which could lead the way to creating samples of rare blood artificially. REUTERS/Jean-Paul Pelissier (FRANCE HEALTH SOCIETY SCI TECH)

RP4DRIHYHEAA A Vietnamese researcher shows a bottle of diluted blood sample to test for bird flu at a newly-established laboratory at Hanoi's National Paediatric Hospital February 17, 2004. Tests for the H5N1 virus have been shortened to two hours from a week previously, with help from the World Health Organisation. A 15-year-old boy and a 22-year-old man are being treated for bird flu in Vietnam, breaking a nearly week-long lull in the country of new reports of the disease that has taken at least 20 lives in Asia and caused the death of millions of poultry, health officials said on Monday. REUTERS/Stringer HBM/BM

RP4DRIHYHCAA A Vietnamese researcher puts a blood sample tube into a centrifuge to test for bird flu at a newly-established laboratory at Hanoi's National Paediatric Hospital February 17, 2004. Tests for the H5N1 virus have been shortened to two hours from a week previously, with help from the World Health Organisation. A 15-year-old boy and a 22-year-old man are being treated for bird flu in Vietnam, breaking a nearly week-long lull in the country of new reports of the disease that has taken at least 20 lives in Asia and caused the death of millions of poultry, health officials said on Monday. REUTERS/Stringer HBM/CP

PBEAHUMPKDX UNDATED FILE PHOTO - An undated handout photo from the Shiloov Medical Technologies Ltd. shows a lab worker at a machine where the ShiloovTubes, used in the diagnosis of HIV blood samples, are manufactured. The medical centre claims it has developed a blood diagnosis system that is able to detect the HIV virus far earlier than conventional methods. The Shiloov Tube helps detect the presence of HIV antibodies in a patient's blood by accelerating their development in as little as one to two weeks after exposure. The developer, an Israeli woman, says the new process would help protect blood bank supplies from HIV contamination and allow people exposed to HIV to get diagnosis and treatment earlier.

RP1DRIDNHBAA UNDATED FILE PHOTO - An undated handout photo from the Shiloov Medical Technologies Ltd. shows a lab worker at a machine where the ShiloovTubes, used in the diagnosis of HIV blood samples, are manufactured. The medical centre claims it has developed a blood diagnosis system that is able to detect the HIV virus far earlier than conventional methods. The Shiloov Tube helps detect the presence of HIV antibodies in a patient's blood by accelerating their development in as little as one to two weeks after exposure. The developer, an Israeli woman, says the new process would help protect blood bank supplies from HIV contamination and allow people exposed to HIV to get diagnosis and treatment earlier.AIDS ISRAEL